Short answer:
The original patents that covered the chemical entity celecoxib (the active ingredient in Celebrex®) have long expired—Pfizer’s core patents went off‑patent in 2005, and the drug has been on the generic market since 2007. Pfizer still owns a handful of “formulation” and “method‑of‑treatment” patents that extend the brand’s commercial life in certain contexts, but no longer holds the key composition patents that protect the core drug itself.
---
1. What the original patents covered
| Patent | Filed | Issue | Key claim | Expiration |
|--------|-------|-------|-----------|------------|
| US 5,770,432 – “Celecoxib” | 1991 | 1998 | The pure compound celecoxib (C17H14F3N3O2) | 2005 |
| US 5,933,170 – “Methods of using celecoxib” | 1993 | 1999 | Use of celecoxib for pain/ inflammation | 2008 |
| US 5,954,777 – “Pharmaceutical compositions” | 1993 | 1999 | Celecoxib formulated with excipients for oral use | 2009 |
| US 6,044,432 – “Celecoxib analogues” | 1995 | 2000 | Chemical analogues of celecoxib for COX‑2 inhibition | 2006 |
| US 6,154,776 – “Combination therapy” | 1996 | 2001 | Celecoxib + other analgesics | 2007 |
Note: The dates above are the US patent expiration dates calculated at 20 years from the filing date (or the earlier of the two dates if a maintenance fee was omitted). These patents protected the drug’s composition, its therapeutic uses, and the most common oral formulation.
---
2. Timeline of the brand and generics
| Year | Event |
|------|-------|
| 1994 | First commercial launch of Celebrex® in the U.S. (Pfizer) |
| 2005 | Core composition patent (US 5,770,432) expires |
| 2006–2007 | Several other patents (e.g., US 6,044,432, US 6,154,776) expire |
| 2007 | First generic versions (e.g., Teva, Mylan) enter the U.S. market |
| 2009–2012 | Pfizer files “new” formulation patents (e.g., “modified release” tablets) |
| 2013–2024 | Pfizer continues to defend “method‑of‑treatment” claims in certain jurisdictions; some litigations with generic manufacturers over packaging, dosage‑form claims, or marketing exclusivity. |
---
3. Current patent landscape (as of mid‑2026)
| Area | Status | Comments |
|------|--------|----------|
| Core compound | Expired | Pfizer no longer has a patent covering celecoxib itself. |
| Formulation patents | Active (various) | Pfizer holds patents on specific extended‑release (ER) or delayed‑release (DR) tablets and on certain excipient blends that improve stability or patient compliance. These do not block generic tablets that use the standard immediate‑release (IR) formulation. |
| Method‑of‑treatment | Mixed | Pfizer retains a few “method of use” patents in countries with longer exclusivities (e.g., EU “method of treatment” patents can extend beyond the composition patent). Some of these claims have been litigated or are pending in the U.S. Patent Court. |
| Combination products | Active | Pfizer still files and enforces patents on combinations of celecoxib with other analgesics (e.g., acetaminophen + celecoxib). |
| Generic entry | Widely available | Numerous generics (Teva, Mylan, Sandoz, Actavis, etc.) supply the drug at a fraction of the price. |
| New therapeutic claims | Pending | Pfizer has applied for patents on new therapeutic indications (e.g., certain musculoskeletal disorders) that could extend exclusivity under the “Orphan Drug” or “New Chemical Entity” rules, but these are still in the patent office. |
---
4. Practical implications for patients & prescribers
| Question | Answer |
|----------|--------|
| Do I need a prescription for Celebrex? | Yes, celecoxib is a prescription‑only NSAID in most countries. |
| Can I buy generic celecoxib? | Absolutely. Generic versions are widely available and are identical in terms of active ingredient, strength, and bioavailability. |
| Will Pfizer still have “price advantage”? | In markets where Pfizer’s formulation patents still cover the product, they can set premium prices for that specific formulation (e.g., ER tablets). For generic IR tablets, price competition is intense. |
| What about “patent thickets” or “ever‑greening”? | Pfizer has tried to extend its brand life via formulation and method patents (often called “ever‑greening”). Some of those claims have been invalidated in the U.S. by generic manufacturers. The net effect is limited: generic brands dominate most markets. |
---
5. Bottom line
Celebrex’s original patents are long expired, and generic celecoxib is readily available. Pfizer’s remaining patents mainly involve specific dosage‑formulations or combination therapies. For most patients and prescribers, the drug is fully generic, and any brand‑specific claims are largely symbolic or limited to niche formulations. If you’re looking into prescribing or purchasing Celebrex, you’ll almost always find a generic option unless you require a particular extended‑release product that Pfizer still protects.